Evidence map›Paper›PMID 39542951›Full record

ReviewAbdominal radiology (New York)2025

MRI after focal therapy for prostate cancer: what radiologists must know?

Rozita Jalilianhasanpour, Sandeep Arora, Bahar Mansoori, Steve Raman, Bernadette Marie Greenwood, Preston Sprenkle, George Schade, Mari Camacho, Nastaran Hosseini, Antonio Westphalen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rozita JalilianhasanpourDepartment of Radiology, University of Washington, Seattle, WA, USA. rjalil@uw.edu.
Sandeep AroraDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Bahar MansooriDepartment of Radiology, University of Washington, Seattle, WA, USA.
Steve RamanDepartment of Radiology, University of California Los Angeles, Los Angeles, CA, USA.
Bernadette Marie GreenwoodHalo Diagnostics, Indian Wells, CA, USA.
Preston SprenkleDepartment of Urology, Yale School of Medicine, New Haven, CT, USA.
George SchadeDepartment of Urology, University of Washington, Seattle, WA, USA.
Mari CamachoUniversity of Hawaii School of Medicine, Honolulu, HI, USA.
Nastaran HosseiniDepartment of Radiology, University of Washington, Seattle, WA, USA.
Antonio WestphalenDepartment of Radiology, University of Washington, Seattle, WA, USA. acwestph@uw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal therapy (FT) is a rapidly growing field aiming to minimize the side effects of whole gland treatments in patients with localized prostate cancer and multiparametric MRI plays an important role in patient selection, treatment planning, and post-treatment monitoring. This article reviews the currently available prostate cancer FT techniques, discusses the key imaging findings that affect patient selection and treatment planning, and illustrates the spectrum of expected and abnormal post-treatment MRI findings.

Indexed as

Magnetic Resonance ImagingProstatic NeoplasmsHumansMalePatient SelectionFocal TherapyImagingMRIProstate CancerTreatment

Identifiers

PMID39542951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.